M&A Deal Summary |
|
|---|---|
| Date | 2025-07-23 |
| Target | Novaestiq |
| Sector | Consumer Products |
| Buyer(s) | Waldencast |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2020 |
| Sector | Consumer Products |
| Employees | 335 |
| Revenue | 274M USD (2024) |
Waldencast’s vision is to build a global beauty and wellness operating platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. The Company intends to seek brands with a direct connection to today’s evolving consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. Waldencast was founded in 2020 and is based in London, England.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Consumer Products M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-15 |
Obagi
Long Beach, California, United States Obagi is a physician-dispensed brand in the dermo-cosmetic space, the highest-growth category in skin care. Obagi's product portfolio includes brands Obagi Nu-Derm®, Condition & Enhance®, Obagi-C® Rx, ELASTIDerm® and CLENZIDerm®. |
Buy | - |
